AUTOMATED GENERATION AND ANALYSIS OF ORGANOIDS
20220049219 · 2022-02-17
Inventors
- Jan Markus BRUDER (Munster, DE)
- Henrik RENNER (Munster, DE)
- Hans Robert SCHÖLER (Munster, DE)
- Martha Anna GRABOS (Munster, DE)
- Mandy OTTO (Munster, DE)
Cpc classification
C12N2501/999
CHEMISTRY; METALLURGY
G01N1/30
PHYSICS
C12N2501/16
CHEMISTRY; METALLURGY
C12N2506/45
CHEMISTRY; METALLURGY
C12N2501/115
CHEMISTRY; METALLURGY
C12N2533/90
CHEMISTRY; METALLURGY
C12N2501/01
CHEMISTRY; METALLURGY
International classification
G01N1/30
PHYSICS
Abstract
The present invention relates to a method of producing organoids, said method comprising or consisting of: (a) seeding a plurality of tissue-specific precursor cells into a container; (b) allowing to occur (i) aggregation of said cells; and (ii) maturation of the aggregate formed in (i) into a single organoid; wherein said method does not comprise embedding of said cells or said aggregates into a gel.
Claims
1. A method of producing organoids, said method comprising or consisting of: (a) seeding a plurality of tissue-specific precursor cells into a container; (b) allowing to occur (i) aggregation of said cells; and (ii) maturation of the aggregate formed in (i) into a single organoid; wherein said method does not comprise embedding of said cells or said aggregates into a gel.
2. The method of claim 1, wherein (i) said organoids are neural organoids, preferably midbrain organoids or non-patterned homogeneous brain organoids; and said tissue-specific precursor cells are neuronal tissue-specific precursor cells, preferably small molecule neuronal precursor cells (smNPCs); (ii) said organoids have a reproducible or homogeneous size and/or cellular composition, homogenous preferably meaning a standard deviation of less than 20% of the mean or less; (iii) step (b) comprises (b-i) culturing in aggregation medium, preferably for about two days, said aggregation medium preferably comprising polyvinyl alcohol; (b-ii) culturing a maturation medium; and (b-iii) preferably, between (b-i) and (b-ii), culturing in ventral patterning medium, preferably for about four days; (iv) said plurality of cells is between about 100 and about 1000000, preferably about 10000 cells; and/or (v) said container is a well of a multiwell plate, wherein preferably a plurality of wells or each well of said multiwell plate is seeded with a plurality of said cells, such that a multiwell plate is obtained, wherein a plurality of wells or each well contains one single organoid.
3. An organoid or a plurality of organoids obtained by the method of any one of the preceding claims.
4. An organoid or a plurality of organoids, wherein (a) said organoid(s) is/are (a) neural organoid(s), preferably (a) midbrain organoid(s) or (a) non-patterned homogeneous brain organoid(s); (b) said organoid(s) exhibit(s) (i) a plurality of concentric zones, each zone differing from any of the other zones with regard to cellular composition and organization, preferably at least three zones; and/or (ii) said organoid(s) exhibit tissue-specific cellular activity, preferably, in case of neural organoids, electrical activity in neurons; and/or (c) said plurality of organoids is homogenous in terms of structure and/or size; wherein said organoid or said plurality is preferably obtained by the method of claim 2.
5. A multiwell plate, wherein a plurality of wells contain each one single organoid or each well contains one single organoid, wherein preferably a plurality of the organoids or each organoid is as defined in claim 3 or 4 or obtained by the method of claim 1 or 2.
6. Use of tissue-specific precursor cells for organoid production, wherein no use is made of a gel for embedding cells or aggregates, wherein preferably said tissue-specific precursor cells are neuronal tissue-specific precursor cells, preferably small molecule neuronal precursor cells (smNPCs).
7. A method of preparing organoids or spheroids for analysis, said method comprising or consisting of: (a) staining said organoids or spheroids; (b) performing tissue clearing with said organoids or spheroids.
8. The method of claim 7, wherein (a) said staining is effected with (i) an antibody, preferably with a primary and with a secondary antibody, wherein staining with said primary antibody and/or said secondary antibody is effected for about 5 to about 10 days, preferably about 6 days; (ii) a fluorescent label; (iii) a luminescent label; (iv) a radioactive label; and/or (b) said clearing is benzyl alcohol and benzyl benzoate (BABB)-based clearing, wherein preferably said clearing is performed in cyclo-olefin containers, more preferably in cyclo-olefin multiwell plates.
9. The method of claim 7 or 8, wherein (a) said method does not comprise sectioning of said organoids or spheroids and/or said staining is whole mount staining; and/or (b) said organoids are organoids of claim 3 or 4 or are obtained by the method of claim 1 or 2.
10. A method of analysing organoids or spheroids, said method comprising or consisting of the method of any one of claims 7 to 9; and (c) analysis of stained and cleared organoids or spheroids, preferably (c-i) optical analysis, said optical analysis preferably comprising microscopy and/or image analysis; (c-ii) genetic analysis such as RNA sequencing; and/or (c-iii) protein analysis such as mass spectrometry or Western blotting.
11. A method of preparing and analysing organoids, said method comprising or consisting of the method of claim 1 or 2 and the method of claim 10.
12. A method of identifying modulators of organoids, of organoid formation, and/or of organoid-specific function, said method comprising or consisting of (a) (i) adding a test compound to an organoid, preferably of claim 3 or 4 or obtained by the method of claim 1 or 2; (ii) adding a test compound to tissue-specific precursor cells, followed by performing the method of claim 1 or 2; or (iii) performing the method of claim 1 or 2, wherein a test compound is added at one or more time points during said performing the method of claim 1 or 2; (b) performing the method of claim 10; (c) comparing the result of said analysis in the presence of said test compound with the result of said analysis in the absence of said test compound, wherein a difference is indicative of a modulator.
13. The method of claim 12, wherein (a) if said analysis is indicative of a functional improvement of said organoid, of organoid formation and/or of organoid-specific function, said test compound is a lead compound, said method optionally further comprising or further consisting of developing said lead compound to yield a drug; or (b) if said analysis is indicative of a decrease of function of said organoid and/or of negative interference with organoid formation and/or with organoid-specific function, this is indicative of said test compound being toxic.
14. The method of any one of claims 1, 2 or 7 to 13, wherein said method is performed (a) in an automated manner; and/or (b) in high-throughput format, preferably using multiwell plates, a pipetting robot, automated liquid handling, a plate reader and/or means for plate transportation.
15. A kit comprising or consisting of (a) tissue-specific precursor cells, preferably neuronal tissue-specific precursor cells, more preferably smNPCs; and (b) media, said media comprising or consisting of (b-i) aggregation medium, said aggregation medium preferably comprising polyvinyl alcohol; (b-ii) maturation medium; and (b-iii) optionally, ventral patterning medium.
Description
[0082] The Figures show:
[0083]
[0085]
[0087]
[0089]
[0091]
[0092]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101] The Examples illustrate the invention.
EXAMPLE 1
Methods
[0102] smNPC Culture
[0103] All cells and organoids were maintained at 37° C. and 5% CO2 unless otherwise noted. We cultured human small molecule precursor cells (smNPCs) with minor modifications as previously described22. Briefly, we grew smNPCs in 0.0125% (v/v) Matrigel (BD)-coated 6-well plates (Sarstedt) in N2B27 medium supplemented with the small molecules smoothened agonist (0.5 μM, SAG, Cayman Chemical) and CHIR 99021 (3 μM, Axon MedChem). N2B27 consisted of DMEM-F12 (Thermo Fisher) and Neurobasal Medium (Thermo Fisher) at a 1:1 ratio, enriched with 1:400 diluted N2 supplement (Thermo Fisher), and 1:200 diluted B27 supplement without vitamin A (Thermo Fisher), 1% penicillin/streptomycin/glutamine (Thermo Fisher), and 200 μM ascorbic acid (Sigma-Aldrich). Typically, we exchanged medium every other day. The cells were split every 5-7 days at a splitting ratio of 1:10 to 1:20 via accutase treatment (Sigma-Aldrich) for ca. 15 min at 37 C, yielding a single cell solution. To stop the digestion, the cells were diluted in DMEM-F12 with 0.1% BSA (Thermo Fisher) and centrifuged at 1200 g for 2 minutes. The cell pellet was resuspended in fresh smNPC medium (N2B27 with SAG and CHIR) and plated on Matrigel-coated 6-well plates.
AMO Generation
[0104] After digestion by accutase, we seeded 9000 smNPCs in each well of a conical 96-well plate (Thermo Fisher) in smNPC medium and allowed them to aggregate for 2 days. To increase inter-cell adhesion, we added 0.4% (w/v) polyvinyl alcohol (PVA). Starting at day 2, cells undergo ventral patterning over 4 days in 2 feedings by removal of CHIR99021 in the continued presence of SAG. The addition of 0.5 ng/mL brain derived neurotrophic factor (BDNF, PeproTech) and 1 ng/mL glial cell line-derived neurotrophic factor (GDNF, PeproTech) boost maturation and cell survival during the rest of the neural maturation. After ventralization, we removed SAG on day 6, further supported midbrain differentiation and maturation by the addition of 0.5 ng/mL transforming growth factor beta 3 (TGF8-3), and 100 μM dibutyryl cyclic adenosine monophosphate (dbcAMP, Sigma-Aldrich). A single dose of 5 ng/mL Activin A was added on day 6 only. Depending on the desired degree of maturity, the duration of the maturation phase can be prolonged to 100 days and longer.
Generation of NABOs
[0105] Like the automated midbrain organoids, the non-patterned automated brain organoids were generated, maintained and analyzed in a fully automated fashion. The principle workflow remains identical, only media formulations and media timings differ, demonstrating the flexibility of the method of the invention to accommodate generation of a variety of different, preferably neural structures. In short, the method for generating the NABOs is as follows:
[0106] After digestion by accutase, we seeded 9000 smNPCs in each well of a conical 96-well plate (Thermo Fisher) in smNPC medium and allowed them to aggregate for 2 days. To increase inter-cell adhesion, we added 0.4% (w/v) polyvinyl alcohol (PVA) to the seeding medium. The smNPC medium is based on N2B27 medium supplemented with the small molecules smoothened agonist (0.5 μM, SAG, Cayman Chemical) and CHIR 99021 (3 μM, Axon MedChem). N2B27 medium consisted of DMEM-F12 (Thermo Fisher) and Neurobasal Medium (Thermo Fisher) at a 1:1 ratio, enriched with 1:400 diluted N2 supplement (Thermo Fisher), and 1:200 diluted B27 supplement without vitamin A (Thermo Fisher), 1% penicillin/streptomycin/glutamine (Thermo Fisher), and 200 μM ascorbic acid (Sigma-Aldrich). Starting at day 2, the aggregates undergo undirected neural differentiation by withdrawal of SAG and CHIR from the medium and addition of 1 ng/mL brain derived neurotrophic factor (BDNF, PeproTech) and 1 ng/mL glial cell line-derived neurotrophic factor (GDNF, PeproTech). These growth factors boost maturation and cell survival during the rest of the neural maturation. Depending on the desired degree of maturity, the duration of the maturation phase can be prolonged to 100 days and longer. For analysis, organoids were whole mount stained and optically cleared as disclosed herein.
Size Measurement of Organoids
[0107] For size measurements of both AMOs and NABOs, we took brightfield images of randomly selected organoids using a stereo microscope (Leica MZ10 F, camera: Leica DFC425 C). Images were processed with ImageJ/Fiji (Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676-682 (2012)) using a custom-tailored standardized workflow. The auto threshold function was used to discriminate organoids from the background followed by a measurement of their area with the analyze particles function. The measured area corresponds to the largest cross-section of the organoid. Data were outputted to Microsoft Excel and GraphPad Prism v7.0 (Graphpad Software, Inc.) for further analysis.
Whole Mount Staining and Clearing
[0108] In order to analyze protein expression in 3D in a HTS-compatible manner, we adapted a whole mount staining protocol based on Lee et al. ACT-PRESTO: Rapid and consistent tissue 579 clearing and labeling method for 3-dimensional (3D) imaging. Sci Rep 6, 18631 (2016) for organoids and optimized it for use in an automated liquid handling system. After fixation with 4% PFA (VWR) for 10-15 minutes, we stained the organoids with primary and secondary antibodies (Alexa Fluor secondary antibodies, Thermo Fisher) for 6 days each. We diluted the antibodies in a blocking and permeabilization solution (6% BSA, 0.5% Triton-X 100 (Roth), 0.1% (w/v) sodium azide (Sigma-Aldrich) in PBS (Sigma-Aldrich)) and renewed it every 2 days. Between primary and secondary antibody incubation as well as after the staining procedure we washed the organoids 5 times for 1 h with 0.1% Triton X-100 in PBS. This extremely long staining procedure allows the antibodies to fully penetrate the organoids despite their large size and high density. To enable full penetration by microscope illumination, the whole mount staining procedure is followed by BABB-based tissue clearing Dent, J. A., Polson, A. G. & Klymkowsky, M. W. A whole-mount immunocytochemical analysis of the expression of the intermediate filament protein vimentin in Xenopus. Development 105, 61-74 (1989). First, the organoids were dehydrated stepwise through a methanol (Roth) series (25%, 50%, 70%, 90%, 100%, 15 minutes each). Next, they were transferred to an organic solvent-resistant cyclo-olefin 96-well plate (“Screenstar”, Greiner Bio-One). The samples were incubated for 30 minutes in 1:1 methanol/389 BABB (benzyl benzoate (Sigma-Aldrich) and benzyl alcohol (Sigma-Aldrich) 1:1) and subsequently kept in BABB for imaging. We used Imaris v8.4 (Bitplane, Oxford Instruments) for 3D rendering of confocal slices (
Quantitative Real Time PCR
[0109] We performed RNA isolation for quantitative real time PCR (qPCR) analysis using the NucleoSpin RNA XS kit (Macherey-Nagel) according to the manufacturer's instructions. Depending on their age, we pooled 32 (d6), 24 (d16), or 18 (d30) organoids from one batch in order to yield enough RNA for downstream analysis. We determined RNA concentration and purity using a NanoDrop 8000 spectrophotometer (Thermo Fisher) and performed reverse transcription according to standard protocols using 1000 ng RNA per reaction. For quantification of gene expression, we used the Biomark 48.48 integrated fluidic circuit (IFC) Delta Gene assay (Fluidigm) according to the manufacturer's instructions. Briefly, following 14 cycles of preamplification, the samples were subjected to an exonuclease I (New England Biolabs) treatment (37° C. for 30 min and 80° C. for 15 min) and diluted twentyfold with DNA Suspension buffer (TEKnova). The samples (in duplicates) and assay mixtures were loaded onto a 48.48 microfluidic ICF chip and run on the BioMark real-time PCR reader (Fluidigm) where they were amplified and measured according to manufacturer's instructions. Data analysis was performed using the BioMark real-time PCR analysis software 4.3.1 (Fluidigm) standard settings. Data was transferred to Microsoft Excel for further processing and GraphPad Prism v7.0 for plotting. GAPDH served as housekeeping gene.
Calcium Imaging
[0110] For calcium imaging, we added 10 μM cell-permeant Fluo-4 AM (Thermo Fisher) diluted in organoid medium to the organoids and incubated for 60 minutes at 37° C. Imaging was performed using a Dragonfly spinning disc confocal microscope (Andor, Oxford Instruments) at a frequency of 10 Hz for 4 minutes. Data analysis was performed using ImageJ/Fiji (Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676-682 (2012)). First, different ROls were defined as depicted in
iPSC Culture
[0111] Human iPSC culture was performed feeder-free using modified FTDA medium (Frank, S., Zhang, M., Scholer, H. R. & Greber, B. Small molecule-assisted, line-independent maintenance of human pluripotent stem cells in defined conditions. PLoS One 7, e41958 (2012)) in 0.0125% (v/v) Matrigel-coated 6-well plates with a previously described healthy control line. FTDA medium consisted of DMEM-F12 supplemented with 1% human serum albumin (Biological Industries), 1% Chemically Defined Lipid Concentrate (Life Technologies), 0.1% Insulin-Transferrin-Selenium (BD), 1% penicillin/streptomycin/glutamine. We fed the iPSCs daily and added 10 ng/mL FGF2 (PeproTech GmbH), 0.2 ng/mL TGFβ3 (PeproTechGmbH), 50 nM Dorsomorphin (Santa Cruz), 5 ng/mL Activin A (eBioscience), 20 nM C59 (Tocris) before each media exchange. We split the iPSCs as single cells every 3-5 days using accutase for ca. 10 minutes at 37° C. We transferred 600.000 cells per well of a 6-well plate to be seeded to DMEM-F12 with 0.1% BSA and centrifuged at 1200 g for 2 minutes. We resuspended the cell pellet in fresh FTDA medium supplemented with 1:2000 ROCK inhibitor Y-27632 (tebu-bio) and plated the iPSCs on Matrigel-coated 6-well plates.
iPSC-Based Organoid Culture
[0112] For iPSC-derived organoid generation we followed the protocol by Lancaster et al. (Cerebral organoids model human brain development and microcephaly. Nature 501, 373-379 (2013)) with minor modifications. Briefly, we dissociated iPSCs to single cells by accutase treatment and plated 9000 cells per well in a conical 96 well plate in low FGF stem cell medium (DMEM-F12 with knockout serum replacement (KOSR, Thermo Fisher) 1:5, fetal bovine serum (Biochrom) 1:33.3, 1% penicillin/streptomycin/glutamine, 1% non-essential amino acids (NEAA, Thermo Fisher), β-mercaptoethanol (Thermo Fisher) 1:143, 4 ng/μL FGF2, 50 μm ROCK inhibitor Y-27632, and 0.4% PVA on seeding day only to facilitate aggregation). We exchanged the medium every other day, FGF2 and Y-27632 were withdrawn on day 6. Neural induction was started on day 8 (neural induction medium: DMEM-F12 with KOSR 1:5, 1% penicillin/streptomycin/glutamine, 1% 439 non-essential amino acids, N2 supplement 1:100, and Heparin (Sigma-Aldrich) 1 μg/mL) and continued for 6 days with media changes every other day. On day 13, we embedded the aggregates into 30 μL matrigel droplets and transferred them to 6 cm2 suspension tissue culture dishes (Sarstedt) in cerebral organoid differentiation medium (DMEM-F12 and Neurobasal 1:1 with 1% penicillin/streptomycin/glutamine, 1% NEAA, N2 supplement 1:200, B27 supplement without vitamin A 1:100, Insulin (Sigma-Aldrich) 1:4000, and β-mercaptoethanol 1:285714). We placed the culture dishes on a shaker at 37° C. and 5% CO2 and fed the organoids every other day. On day 20 the B27 supplement was replaced by B27 with Vitamin A (Thermo Fisher) and organoids were cultured until day 30/45.
RNA Sequencing
[0113] To isolate RNA of single organoids we used the Direct-zol-96 RNA kit (Zymo Research) according to the manufacturer's instructions. We assessed RNA concentration and purity using a NanoDrop 8000 spectrophotometer and RNA integrity with a Bioanalyzer (Agilent Technologies) per standard protocols. Next, mRNA was enriched using the NEBNext Poly(A) Magnetic Isolation Module (NEB) followed by strand-specific cDNA NGS library preparation (NEBNext Ultra II Directional RNA Library Prep Kit for Illumina, NEB). The size of the resulting library was controlled by use of a D1000 ScreenTape (Agilent 2200 TapeStation) and quantified using the NEBNext Library Quant Kit for Illumina (NEB). Equimolar pooled libraries were sequenced in a single read mode (75 cycles) on the NextSeq 500 System (Illumina) using v2 chemistry yielding in an average QScore distribution of 95%>=Q30 score and subsequent demultiplexed and converted to FASTQ files by means of bcl2fastq v2.20 Conversion software (Illumina).
RNA Sequencing Analysis
[0114] We aligned the RNA sequencing reads to the human genome hg19 with TopHat2 aligner (v2.1.1)46, using default input parameters. Gene annotation from Ensembl (version GRCh37.87) were used in the mapping process. The number of reads that were mapped to each gene was counted using the Python package HTSeq (v0.7.2) (Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015)) with “htseq-count—mo 464 de union—stranded no”. Principal component analysis and differential expression analysis was performed with raw counts using the R package DESeq2 (v1.18.1). Dispersion within groups was calculated using the average distance between data points and centroids. Genes were considered as deregulated if |log 2FC|>2 and FDR<0.05 using Benjamini-Hochberge multiple test adjustment (Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289-300 (1995)). Gene Ontology (GO) term enrichment was analyzed with the bioinformatics web server Gorilla (Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009) and visualized with REViGO40. All RNA sequencing data was deposited to NCBI GEO database.
Quantification of Whole Mount Staining and Clearing
[0115] To assess how quantitative our imaging workflow is, we performed a dilution experiment. We mixed unlabeled smNPCs with different percentages (1.25%, 2.5%, 5%, 10%, 20%, 40%) of CellTracker deep red dye (Life technologies)-labeled cells (labeling according to standard protocols, dye concentration 1:20000) and aggregated them in smNPC maintenance medium with 0.4% PVA. To explore the effects of overall aggregate size on quantitation, we generated aggregates with 100.000 as well as 200.000 cells in total. After 1 day of aggregation, the aggregates were fixed with 4% PFA, subjected to BABB-based tissue clearing, imaged, and analyzed as described below.
High Content Imaging and Analysis
[0116] After staining and clearing, we achieved uniform aggregate positioning within the wells by tilting the plates off the horizontal plane at 60 degrees for 1 minute. Image acquisition was carried out in an Operetta high content imager (Perkin Elmer) and images were analyzed in Harmony 4.1 software. We acquired a total of 16 confocal planes in three channels (DAPI, Sox2-488, and MAP2-647) with an inter-plane spacing of 36.6 μm for a total stack of 549 μm, covering the entire organoid height. To define the organoid region on each image plane, all three channels were summed, filtered with a median filter to remove small localized features and bright areas were identified via the “find image region” function. After cleaning the edge of the organoid region by dilation and erosion steps of 10 and 3 pixels, respectively, we identified bona fide organoids by selecting for regions with a minimum of 300 arbitrary brightness units (abu) and 4000 μm2 size. In order to better isolate Sox2+ nuclei from the general background, we ran a sliding parabola algorithm with a curvature setting of 2 across each image plane in the 488 channel. Nuclei were then identified within each organoid region via the “find nuclei” function, algorithm “M” and further selected to be Sox2+ if they were larger than 10 um2 and brighter than 1200 abu. We excluded image artifacts, small dust particles, and overlapping nuclei by omitting nuclei brighter than 6000 abu and larger than 70 μm2 from further quantification. For final output, the number and total brightness of nuclei in 488 and of organoid regions in 647 were summed for all planes and all fields of view in each well and transferred to Microsoft Excel and TIBCO Spotf ire for further annotation, analysis and plotting. We omitted data from wells that contained dust particles, incompletely imaged organoids due to improper positioning, or organoids that have been damaged or lost during culture or downstream processing. Plate 1, 2, and 3 represent independent differentiations of separately thawed and cultured cells of the same freezing batch.
Electrophysiological Analysis of Single Cells by Patch-Clamping
[0117] Due to the morphology of AMOs (high optical density and the fact that most cell bodies are located in a depth of at least 10-20 μm), it was technically impossible to perform the patch-clamp measurements on intact aggregates. Therefore, the organoids were treated with 1 mg/ml trypsin and then mechanically dispersed to obtain single cells. These were seeded on PDL-coated coverslips and cultured for 1-3 days in AMO medium (we stated the age of AMOs at the time of dissociation). The transmembrane currents were recorded from isolated cells using the whole-cell configuration of the patch-clamp technique (Hamill, O. P., Marty, A., Neher, E., Sakmann, B. & Sigworth, F. J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391, 85-100 (1981)). The patch pipettes were fabricated from borosilicate glass on a Sutter P1000 (Sutter Instrument company) pipette puller. When filled with pipette solution, they had a tip resistance of 4-6 MΩ. Recordings were done using an EPC-10 amplifier (HEKA Elektronik) and Patchmaster aqusition software (HEKA Elektronik). Series resistance, liquid junction potential, pipette and whole-cell capacitance were cancelled electronically. Bath solution contained (mM): NaCl 140, KCl 2.4, MgCl2 1.2, CaCl2 2.5, HEPES 10, D-glucose 10, pH 7.4 and the pipette solution contained (mM): K-aspartate 125, NaCl 10, EGTA 1, MgATP 4, HEPES 10, D-glucose 10, pH 7.4 (KOH). We performed all experiments at room temperature. Recordings of current-voltage relationship (I-V curves) were done in voltage-clamp mode at a holding potential of −70 mV. Recordings of evoked action potentials were performed in current-clamp mode. Data were analyzed using Patcher's Power Tool routine for IgorPro (WaveMetrics), SciDAVis (http://scidavis.sourceforge.net/) and Origin Pro 2019 (Origin Lab). To reveal the shape of I-V curves, single traces were normalized to the peak amplitude and then averaged.
3D Toxicology Assay
[0118] At day 50 we treated AMOs with increasing concentrations (0, 5, 50, 100, 250, 500, 1000 μg/mL) of G418 added directly to the culture medium. After 2 days, we renewed the medium (including identical inhibitor concentrations) and fixed the aggregates after a total of 4 days of treatment. Fixation, whole mount immunostaining for cCasp3 and Sox2 as well as BABB-based clearing was performed as above. Image analysis followed the steps as outlined in the high content analysis section with slight modifications to accommodate the individual brightness, morphology, and background characteristics of the cCasp3 staining. Briefly, after identifying AMOs and Sox2+ cells as described previously, the cCasp3 channel was background corrected by running a sliding parabola algorithm with a curvature setting of 10 across each confocal slice of the AMO. We identified apoptotic cells via the “find nuclei” function in the 647 channel, algorithm “M” and further selected them to be cCasp3+ if they were larger than 11 μm2, smaller than 100 μm.sup.2, and brighter than 2700 abu. We considered cells to be Sox2/cCasp3 double-positive if they fulfilled the criteria for both filters at the same time. The results were outputted to Microsoft Excel, reformatted and then transferred to GraphPad Prism v8.0.2 for plotting, data analysis, and 1050 calculation.
EXAMPLE 2
Results
Automation Enables High Throughput Compatible Production of Homogenous Midbrain Organoids
[0119] Screening applications require biological systems that operate within predictable physiological parameters. In order to limit cellular heterogeneity during differentiation, we produced human neural midbrain organoids starting from pluripotent stem cell (PSC)-derived small molecule neural precursor cells (smNPCs) (Reinhardt, P. et al. Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS One 8, e59252 (2013)). The neural-restricted developmental potential of these cells still allows for the self-organization required for organoid formation (Di Lullo, E. & Kriegstein, A. R. The use of brain organoids to investigate neural development and disease. Nat Rev Neurosci 18, 573-584 (2017); and Monzel, A. S. et al. Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells. Stem Cell Reports 8, 1144-1154 (2017)) but leads to more homogenous organoids compared to PSCs-based protocols. Surprisingly, matrigel embedding turned out to be dispensable and reduces batch-to-batch variability matrigel embedding as do standardized mechanical stresses by using an automated liquid handling system (ALHS). While the resulting automated midbrain organoids (AMOs) are structurally less complex than PSC-derived aggregates, they show little intra- and inter-batch variability in size distribution (
Automated Midbrain Organoids Express Typical Neural and Midbrain Markers and Show Structural Organization
[0120] In order to characterize protein localization in our large scale AMOs (>500 μm diameter) and asses the efficiency of their neural/midbrain differentiation at a cellular resolution and in a HTS-compatible manner, we adapted an extended 3D staining protocol by Lee et al. ACT-PRESTO: Rapid and consistent tissue 579 clearing and labeling method for 3-dimensional (3D) imaging. Sci Rep 6, 18631 (2016) for the use in organoids and combined it with benzyl alcohol and benzyl benzoate (BABB)-based tissue clearing (Dent, J. A., Polson, A. G. & Klymkowsky, M. W. A whole-mount immunocytochemical analysis of the expression of the intermediate filament protein vimentin in Xenopus. Development 105, 61-74 (1989)). We found that BABB-based clearing proved to be both the fastest and most efficient method in a comparison of different clearing protocols. The combination of whole mount staining and clearing allows the 3D reconstruction of entire organoids via confocal imaging and enables further detailed 3D quantification and analysis, for example tracing of neurites throughout the whole organoid, which cannot be performed using typical tissue sectioning procedures (see
[0121] The immunostaining results are depicted as either single confocal optical slices (
[0122] Over time, AMOs mature further. At day 50, expression of the presynaptic marker synaptophysin and postsynaptic marker homer (Tadokoro, S., Tachibana, T., Imanaka, T., Nishida, W. & Sobue, K. Involvement of unique leucine-zipper motif of PSD-Zip45 (Homer 1c/ves1-1 L) in group 1 metabotropic glutamate receptor clustering. Proc Natl Acad Sci USA 96, 13801-13806 (1999)), frequently colocalizing with each other on Map2 positive neuritis (
[0123] In general, the different cell types within the AMOs (i.e. neurons, astrocytes, and neural progenitors) do not form localized structures such as neural rosettes, but are rather organized in four concentric zones around the center of the AMOs (
[0124] Ultrastructural analysis of AMOs (Figure S2) supports the immunofluorescence data revealing a dense 3D cell architecture consistent with neuronal cell bodies surrounded by nerve fibers. Analyzing the nerve fibers at a higher magnification, regular spaced neurofilaments and microtubules can be identified. Moreover, vesicles with the characteristic size and localization of synaptic vesicles are frequently found within these nerve fibers.
[0125] Further quantitative real time PCR (qPCR) analysis demonstrates increasing expression levels of various neural (DCX, Map2, NEFL, NeuN, TBR2, TUBB3, Syt1), midbrain (EN1, GIRK2, MIXL1, NURR1, TH), and glia-specific (GLAST, MBP, S100b) markers at different developmental stages with concomitant decreases in neural precursor markers (Brn2, nestin, Pax6, Sox1, Sox2), confirming neural midbrain maturation over time (
Calcium Imaging Reveals Spontaneous and Synchronized Activity Throughout Entire Organoids
[0126] To assess the functional coupling of individual cells within the AMOs we performed Fluo-4 acetoxymethyl ester (AM)-based calcium imaging, which can be used as a readout for spiking activity of neurons (Grienberger, C. & Konnerth, A. Imaging calcium in neurons. Neuron 73, 862-885 (2012)). In addition to spontaneous activity of individual cells, we observed organoid-wide synchronous and periodic calcium spikes in all analyzed organoids (n=5). To characterize this behavior further, we defined different regions of interest (ROIs) and assessed the change in fluorescence intensity over time in each region (
RNA Sequencing Reveals Lower Intra- and Inter-Batch Variability in Automated Midbrain Organoids Compared to Established Protocols
[0127] To examine the variance of AMOs on the gene expression level, we performed RNA sequencing of single organoids from three different batches of AMOs and one batch of manually produced iPSC-derived organoids following the established protocol from Lancaster et al. (Cerebral organoids model human brain development and microcephaly. Nature 501, 373-379 (2013)) as controls. We sequenced the AMOs at day 30 and the iPSC-derived organoids at day 30 and 45 for a more equivalent comparison, as the latter need to pass through a neural progenitor phase first before entering their neural maturation. This comparison revealed that AMOs are more reproducible intra- and inter-batch than current standard protocols, as the dispersion of whole genome expression levels measured via principal component analysis (PCA,
[0128] Further gene ontology (GO) (Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29 (2000); and Supek, F., Bosnjak, M., Skunca, N. & Smuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 6, e21800 (2011)) analysis of the genes significantly upregulated (padj.<0.05) in day 30 AMOs compared to day 45 iPSC-derived organoids (
[0129] In screening settings, the wells at the edges of plates often display different readouts than those located further towards the center of the plate (“edge-effects”) (Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24, 167-175 (2006)). Therefore, we decided to sequence half of a 96-well plate for one AMO batch and tested for differences resulting from well location within the plate (group “1 inside”=center plate vs. “1 outside”=edge in
Automated Whole Mount Immunostaining is Highly Quantitative 166 and Reveals Homogeneity of Automated Midbrain Organoids
[0130] While immunofluorescence-based screening-compatible techniques of whole organoids have been reported, they can only detect cells in the outer layers of large organoids (Vergara, M. N. et al. Three-dimensional automated reporter quantification (3D-ARQ) technology enables quantitative screening in retinal organoids. Development 144, 3698-3705 (2017)), use small aggregates of approximately 100 μm diameter (Verissimo, C. S. et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife 5 (2016)), or cystic organoids (Czerniecki, S. M. et al. High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping. Cell Stem Cell 22, 929-940 e924 (2018)) that can be penetrated by antibodies and fluorescence illumination more easily. In contrast, our workflow allows the quantification of entire dense, large-scale organoids (>800 μm diameter) with single cell resolution and high sensitivity, as highlighted by a dose-response assay for 3D cellular detection (
[0131] Next, we demonstrated the homogeneity of AMOs on the protein level. A fully automated 96-well based AMO whole mount optical analysis (
[0132] Positional analysis detected effects of plate position (edge effects) for Map2 levels but not Sox2 levels with about 10% reduced Map2 brightness of organoids in the center of the plate (
Automated Midbrain Organoids Allow Toxicity Evaluation in Specific Cellular Subpopulations at the Single Cell Level in a Fully Automated High Throughput Screening Format
[0133] To assess the ability of our workflow to quantify drug effects, we treated AMOs with increasing concentrations of the known cytotoxic compound G418 and stained for the apoptosis marker cleaved caspase 3 (cCasp3) together with Sox2. Plotting the number of apoptotic cCasp3+ cells against the logarithmic drug concentration revealed a typical, sigmoidal dose-response curve (
Homogeneity—AMOs of the Invention, NABOs of the Invention, and Prior Art Organoids
[0134] AMOs are Significantly More Homogeneous than Other Published Brain Organoids with Regard to Overall Morphology and Size
[0135] See
The Internal Organization/Structure of State-of-the-Art Brain Organoids is Highly Variable and Unpredictable Compared to AMOs
[0136] See
Compared to Only Other Midbrain Organoids, AMOs Still Show the Highest Level of Homogeneity
[0137] See
Analysis of Cell Composition Reveals Large Variability in State-of-the-Art Organoids
[0138] See
NABOs of the Invention
[0139] See